Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution

Hosing, Chitra; Bassett, Roland L.; Dabaja, Bouthaina S.; Talpur, Rakhshandra; Alousi, Amin M.; Ciurea, Stefan O.; Popat, Uday; Qazilbash, Muzaffar H.; Shpall, Elizabeth J.; Oki, Yasuhiro; Nieto, Yago; Pinnix, Chelsea C.; Fanale, Michelle A.; Maadani, Farzaneh; Donato, Michèle; Champlin, Richard E.; Duvic, Madeleine

doi:10.1093/annonc/mdv473

Cited by 92 publications

(62 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another case series, 47 MF/SS patients with a median of 6 prior therapy regimens, an age range of 9-72 years, and a Karnofsky index of 70% received alloSCT; 50% of the patients relapsed, and the NRM was 17% at 2 years. The authors reported a superior outcome in SS patients without large-cell transformation [49]. Further studies, mostly conducted with a younger and thus not representative patient selection, found comparable results with relapse being the most common reason for transplantation failure [50,51].…”

Section: Allogeneic Stem Cell Transplantationmentioning

confidence: 94%

Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation

et al. 2017

View full text Add to dashboard Cite

Cutaneous T-cell lymphomas (CTCL) are a rare and biologically heterogeneous malignant entity comprising mycosis fungoides and Sézary syndrome as the most common subtypes. The current treatment outcome is characterized by high rates of relapse, but survival is usually not significantly shortened in low-stage disease. This is different in tumor-stage disease or aggressive CTCL subtypes where survival is significantly reduced. Recent advances have been made on several levels of tumor biology: Whole genome sequencing has resulted in novel strategies of NF-κB or JAK inhibition, ongoing translational research has revealed new targets like CD30 or CCR4, and, finally, research focusing on impaired immunosurveillance has gained more importance. Based on the growing knowledge about the functional roles of the tumor microenvironment and non-malignant infiltrating cells, current research aims to develop novel CTCL treatment strategies. This review focuses on the mounting evidence for efficiently targeting tumor-infiltrating immune cells and thereby modulating the tumor microenvironment and restoring immunosurveillance.

show abstract

Section: Allogeneic Stem Cell Transplantationmentioning

confidence: 94%

Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation

et al. 2017

View full text Add to dashboard Cite

show abstract

“…TSEBT followed by AHSCT may represent a feasible treatment with long-term remissions in selected patients with advanced pCTCL [20,21]. In the case of skin relapse, salvage therapy with low-dose radiation-based therapies (local RT or TSEBT) can be conducted safely with a high ORR (90-100%) [44,57,58].…”

Section: Tsebt Resultsmentioning

confidence: 99%

“…In addition, some novel agents and immunotherapies have been reported to have efficacy for the treatment of advanced MF and SS [11,16,18,19]. Finally, allogeneic hematopoietic stem cell transplantation (AHSCT) has emerged as a feasible modality in patients with advanced pCTCL [20,21].…”

Section: Current Therapeutic Options For Pctclmentioning

confidence: 99%

“…A combination of TSEBT and ECP (for 6 months) resulted in a CRR of 74% in patients with erythrodermic MF, with a significant improvement in DFS and cause-specific survival [61]. In SS, combined immunomodulatory therapy, targeted biologic agents, or TSEBT followed by AHSCT represent promising options with 4-year PFS rates reaching 52% [20,21].…”

Section: Erythrodermic Mf and Ssmentioning

confidence: 99%

See 1 more Smart Citation

Total Skin Electron Beam Therapy as Part of Multimodal Treatment Strategies for Primary Cutaneous T-Cell Lymphoma

Elsayad

Susek

Eich³

2017

Oncol Res Treat

View full text Add to dashboard Cite

Total-skin electron beam therapy (TSEBT) is one of most effective treatments that has been used for cutaneous T-cell lymphoma. Low-dose TSEBT regimens (10-12 Gy) appear to be an effective alternative to conventional-dose TSEBT (30-36 Gy), yielding short-term remission of cutaneous manifestations with minimal toxicity. TSEBT can be administered to patients any time after a diagnosis of mycosis fungoides (MF). Patients requiring rapid relief from cutaneous lesions or symptoms may particularly benefit from TSEBT as an initial therapy. Radiotherapy (RT) dose, boost radiation delivery, maintenance treatment, and radiation tolerability may enhance remission rates and improve relapse-free survival following TSEBT. In addition, salvage local RT or TSEBT may be safely applied with high effectiveness. In this review, we focus on the use of TSEBT in patients with several forms of primary cutaneous T-cell lymphoma, and highlight the potential of low-dose TSEBT as part of a promising therapeutic approach.

show abstract

“…In einer anderen Fallserie wurden 47 MF/SS-Patienten im Alter von 9 - 72 Jahren mit einem Karnofsky-Index von ≥70% nach im Median 6 Vorbehandlungen mit einer alloSCT behandelt; bei 50% trat ein Rezidiv auf, und die NRM nach 2 Jahren betrug 17%. Die Autoren berichten von einem besseren Verlauf bei SS-Patienten ohne großzellige Transformation [49]. Auch weitere Studien gelangten zu vergleichbaren Ergebnissen und identifizierten die Rezidivierung als häufigste Form des Transplantatversagens, allerdings wurden sie meist mit einer jüngeren und daher nicht repräsentativen Patientenauswahl durchgeführt [50,51].…”

Section: Neue Behandlungsansätzeunclassified

Innovative Behandlungskonzepte mit Modulation der Mikroumgebung beim kutanen T-Zell-Lymphom

et al. 2019

View full text Add to dashboard Cite

Kutane T-Zell-Lymphome (CTCL) sinde seltene und biologisch heterogene maligne Erkrankungen; die häufigsten Unterarten sind die Mycosis fungoides und das Sézary-Syndrom. Nach den derzeitigen Therapien ist der Verlauf durch hohe Rezidivraten geprägt, das Überleben ist jedoch in niedrigen Tumorstadien in der Regel nicht signifikant verkürzt. Anders ist dies in höheren Tumorstadien bzw. aggressiveren Subtypen des CTCL; hier ist die Überlebenszeit signifikant reduziert. In jüngster Zeit sind bei verschiedenen Aspekten der Tumorbiologie Fortschritte erzielt worden: Die Genomsequenzierung hat neue Strategien der NF-κB- oder JAK-Inhibition hervorgebracht, in der Translationsforschung wurden neue Zielmoleküle wie CD30 oder CCR4 identifiziert, und nicht zuletzt hat die Forschung zur Beeinträchtigung der Immunüberwachung an Bedeutung gewonnen. Auf der Grundlage der zunehmenden Kenntnis der funktionellen Rollen der Tumormikroumgebung und nichtmaligner infiltrierender Zellen zielt die Forschung gegenwärtig darauf ab, neuartige Behandlungsstrategien bei CTCL zu entwickeln. Im Mittelpunkt dieser Übersichtsarbeit steht die wachsende Evidenz für ein wirksames Targeting tumorinfiltrierender Immunzellen und die dadurch erreichte Modulation der Tumormikroumgebung und Wiederherstellung der Immunüberwachung.

show abstract

Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution

Abstract: Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.

Cited by 92 publications

References 23 publications

Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation

Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation

Total Skin Electron Beam Therapy as Part of Multimodal Treatment Strategies for Primary Cutaneous T-Cell Lymphoma

Innovative Behandlungskonzepte mit Modulation der Mikroumgebung beim kutanen T-Zell-Lymphom

Contact Info

Product

Resources

About